Myeloma Trial, Recruiting NCT06237803 Sponsor: European Myeloma Network B.V. Condition: Myeloma
Back to Myeloma

Myeloma Trial, Recruiting

NCT06237803
Recruiting Not Applicable 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with one of the following conditions: MGUS (an abnormal protein condition that may lead to blood cancer), smouldering multiple myeloma (an early, inactive form of multiple myeloma), multiple myeloma (with or without tumours outside the bone marrow), or plasma cell leukaemia (with or without tumours outside the bone marrow).
  • People who are 18 years of age or older.
  • People who are able to give written consent to participate, and who the trial investigator considers willing and able to follow the trial requirements.

Who may not be able to join:

  • People who have previously received treatment for multiple myeloma — though an exception may apply for those who received one course of urgent treatment due to serious complications, at the treating doctor's discretion (confirm with trial site).
  • People who have had unexpected or serious reactions during past blood donations, such as fainting, chest pain, severe bruising, or allergic reactions.
  • People whose psychological, personal, family, social, or geographical circumstances may make it difficult to follow the trial schedule and requirements.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +31 10702687065

Australian sites

Alfred Hospital, Melbourne,

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
European Myeloma Network B.V.
Registry
ClinicalTrials.gov
Start date
21 December 2022
Est. completion
1 December 2037

Where this trial is recruiting

🇦🇺 Australia 🇦🇹 Austria 🇧🇪 Belgium 🇨🇿 Czechia 🇬🇷 Greece 🇮🇪 Ireland 🇮🇹 Italy 🇵🇹 Portugal 🇷🇸 Serbia 🇨🇭 Switzerland

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Biobank

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov